All You Need to Know About Non-CRF Data in Clinical Trials
We look at the role of non-CRF data in clinical trials, and best practices for…
Certara2024 年 9 月 16 日
What Are SDTM Supplemental Qualifiers?
A detailed look at data that exists out with SDTM variables, known as SDTM supplemental…
Certara2024 年 9 月 16 日
From Development to Patient Impact: Biohaven’s Nurtec™ Success Story
To learn more about Biohaven's success story, read our case study. 阅读案例研究
Certara2024 年 9 月 13 日
4 Ways That Mechanistic Modeling Accelerates Bispecific (and Multispecific) Antibody Drug Development
With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…
Certara2024 年 9 月 12 日
Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report
Check out this article in Fierce Pharma to learn how Certara's US Market Access team…
Certara2024 年 9 月 11 日
Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)
Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…
Certara2024 年 9 月 9 日
Optimizing Avidity of Bispecific Drugs
Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…
Certara2024 年 9 月 9 日
Effects of Tissue Targeting Bispecifics on Therapeutic Window
Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window…
Certara2024 年 9 月 9 日
